<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309449</url>
  </required_header>
  <id_info>
    <org_study_id>922070-1</org_study_id>
    <nct_id>NCT03309449</nct_id>
  </id_info>
  <brief_title>A Usability Assessment of Naloxone by Community Members</brief_title>
  <official_title>A Usability Assessment of Intramuscular, Atomized Intranasal, and Nasal Spray Administration of Naloxone by Community Members</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a usability trial to assess administration of naloxone via intramuscular,&#xD;
      atomized intranasal, and nasal spray routes by nonmedical community members. Participants&#xD;
      will undergo blocked randomization to naloxone kits containing supplies for one of the&#xD;
      aforementioned routes and view an instructional video on how to appropriately administer the&#xD;
      kit they were assigned. Participants will then have the opportunity to administer the&#xD;
      simulated drug to a mannequin designated to simulate the route of administration assigned to&#xD;
      the participant. The rate of successful administration will be determined for each route.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        -  Primary: The successful administration of simulated naloxone. A successful&#xD;
           administration will be defined as administration of the simulated naloxone to the&#xD;
           mannequin head or simulated flesh pad within 10 minutes and without any critical errors&#xD;
           (defined below).&#xD;
&#xD;
        -  Secondary: Total time required to successfully administer the simulated naloxone.&#xD;
&#xD;
      Design: Single site, open-label, randomized usability assessment of intramuscular,&#xD;
      intranasal, and nasal spray administration of simulated naloxone. A convenience sample of&#xD;
      participants will consent to volunteer in the study at a public venue. Participants will&#xD;
      provide verbal consent and will be randomly assigned a simulated naloxone kit containing&#xD;
      either intramuscular, intranasal, or nasal spray administration materials. Participants will&#xD;
      be shown an instructional video demonstrating how to appropriately assemble and administer&#xD;
      the simulated naloxone kit they were randomly assigned. Once the video is complete the&#xD;
      individual will enter a use scenario station where they will be asked to assemble and&#xD;
      administer the simulated naloxone kit to a mannequin (intranasal and nasal spray) or&#xD;
      simulated flesh pad (intramuscular). The participant will be instructed to start and will be&#xD;
      timed until the simulated naloxone has been successfully administered or 10 minutes has&#xD;
      elapsed. The participant will be observed by one trained investigator who will assess for&#xD;
      successful administration of the simulated naloxone and critical errors. The environment will&#xD;
      contain distractors (radio playing) and items that will simulate a community based dwelling&#xD;
      (table, chairs, and an inflatable mattress). The mannequin and simulated flesh pad will be&#xD;
      located on the mattress. Once the participant has successfully administered simulated&#xD;
      naloxone or 10 minutes elapses the timer will be stopped. Successful administration of&#xD;
      simulated naloxone will be defined as administration of the agent without any critical errors&#xD;
      occurring (defined below). Data collected will include demographics (defined below),&#xD;
      successful administration of simulated naloxone, and time to successful administration of&#xD;
      simulated naloxone.&#xD;
&#xD;
      Statistical Methods: All data will be analyzed using IBM SPSS Statistics software.&#xD;
      Demographics data will be analyzed using descriptive statistics for continuous measures and&#xD;
      percentages for categorical measures. The successful administration of naloxone will be&#xD;
      compared between groups using the Chi-square test and a significant difference will be&#xD;
      defined as a p-value of less than 0.05 for the result. The time to administration between&#xD;
      groups will be assessed using a one-way ANOVA and a significant difference will be defined as&#xD;
      a p-value of less than 0.05 for the result.&#xD;
&#xD;
      Data Analysis/Interpretation: As stated above data will be collected to assess both the&#xD;
      successful administration of and time to administration of naloxone. The rate of successful&#xD;
      administration will be reported as a percentage for each of the three groups and analyzed&#xD;
      using the Chi-square test. Successful administration is defined as administration of the&#xD;
      simulated naloxone within 10 minutes without committing any critical errors. Critical errors&#xD;
      are as follows:&#xD;
&#xD;
        -  Intranasal (atomizer): failure to remove both yellow caps from bristoject, failure to&#xD;
           remove cap from simulated naloxone, failure to attach atomizer, failure to attach&#xD;
           simulated naloxone, drug leak prior to administration, administration in only one&#xD;
           nostril, and failure to administer within 10 minutes.&#xD;
&#xD;
        -  Intramuscular: failure to attach the needle to the syringe, failure to remove cap from&#xD;
           simulated naloxone, failure to draw up &gt;90% (0.9 mL) of the simulated naloxone, failure&#xD;
           to puncture simulated flesh pad with needle, failure to push entire volume of fluid in&#xD;
           the syringe into the simulated flesh pad, and failure to administer within 10 minutes.&#xD;
&#xD;
        -  Intranasal (spray): failure to place the tip of the device into one nostril, failure to&#xD;
           depress the device and release the simulated naloxone, failure to administer within 10&#xD;
           minutes.&#xD;
&#xD;
      Time to successful administration will be reported using descriptive statistics (mean time to&#xD;
      administration) and analyzed using a one-way ANOVA. Times for participants who commit a&#xD;
      critical error or who do no administer the simulated naloxone within 10 minutes will not be&#xD;
      included in the analysis.&#xD;
&#xD;
      A route of administration will be considered to be more user-friendly if it demonstrates a&#xD;
      statistically significantly higher rate of successful administration compared to another&#xD;
      route of administration.&#xD;
&#xD;
      Study Procedures: No study procedures will be performed on study participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Administration of Naloxone</measure>
    <time_frame>10 minutes</time_frame>
    <description>A successful administration will be defined as administration of the simulated naloxone to the mannequin head or simulated flesh pad within 10 minutes and without any critical errors (found in detailed description).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Successful Administration of Naloxone</measure>
    <time_frame>10 minutes</time_frame>
    <description>The time required to successfully administer the simulated naloxone will be reported for each group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Drug Overdose</condition>
  <arm_group>
    <arm_group_label>Intramuscular administration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal (Atomizer)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal (Spray)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Syringe and needle</intervention_name>
    <description>Intramuscular administration of simulated naloxone</description>
    <arm_group_label>Intramuscular administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intranasal mucosal atomization device</intervention_name>
    <description>Intranasal atomizer administration of simulated naloxone</description>
    <arm_group_label>Intranasal (Atomizer)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal spray</intervention_name>
    <description>Nasal spray administration of simulated naloxone</description>
    <arm_group_label>Intranasal (Spray)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy adults at least 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severely visually or hearing impaired (defined as: legally deaf, legally blind, unable&#xD;
             to read print size provided on instructional handout, or unable to hear video audio),&#xD;
             previous naloxone administration training, not English proficient, previously&#xD;
             participated in the trial, or pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Eggleston, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York - Upstate Medical University</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <results_first_submitted>October 5, 2021</results_first_submitted>
  <results_first_submitted_qc>October 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intramuscular Administration</title>
          <description>Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.&#xD;
Syringe and needle: Intramuscular administration of simulated naloxone</description>
        </group>
        <group group_id="P2">
          <title>Intranasal (Atomizer)</title>
          <description>Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.&#xD;
Intranasal mucosal atomization device: Intranasal atomizer administration of simulated naloxone</description>
        </group>
        <group group_id="P3">
          <title>Intranasal (Spray)</title>
          <description>Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.&#xD;
Nasal spray: Nasal spray administration of simulated naloxone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intramuscular Administration</title>
          <description>Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.&#xD;
Syringe and needle: Intramuscular administration of simulated naloxone</description>
        </group>
        <group group_id="B2">
          <title>Intranasal (Atomizer)</title>
          <description>Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.&#xD;
Intranasal mucosal atomization device: Intranasal atomizer administration of simulated naloxone</description>
        </group>
        <group group_id="B3">
          <title>Intranasal (Spray)</title>
          <description>Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.&#xD;
Nasal spray: Nasal spray administration of simulated naloxone</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="18" upper_limit="77"/>
                    <measurement group_id="B2" value="51.5" lower_limit="22" upper_limit="81"/>
                    <measurement group_id="B3" value="51" lower_limit="18" upper_limit="79"/>
                    <measurement group_id="B4" value="52" lower_limit="18" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Right Handedness</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>College Degree</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Administration of Naloxone</title>
        <description>A successful administration will be defined as administration of the simulated naloxone to the mannequin head or simulated flesh pad within 10 minutes and without any critical errors (found in detailed description).</description>
        <time_frame>10 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Administration</title>
            <description>Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.&#xD;
Syringe and needle: Intramuscular administration of simulated naloxone</description>
          </group>
          <group group_id="O2">
            <title>Intranasal (Atomizer)</title>
            <description>Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.&#xD;
Intranasal mucosal atomization device: Intranasal atomizer administration of simulated naloxone</description>
          </group>
          <group group_id="O3">
            <title>Intranasal (Spray)</title>
            <description>Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.&#xD;
Nasal spray: Nasal spray administration of simulated naloxone</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Administration of Naloxone</title>
          <description>A successful administration will be defined as administration of the simulated naloxone to the mannequin head or simulated flesh pad within 10 minutes and without any critical errors (found in detailed description).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Successful Administration of Naloxone</title>
        <description>The time required to successfully administer the simulated naloxone will be reported for each group.</description>
        <time_frame>10 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Administration</title>
            <description>Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.&#xD;
Syringe and needle: Intramuscular administration of simulated naloxone</description>
          </group>
          <group group_id="O2">
            <title>Intranasal (Atomizer)</title>
            <description>Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.&#xD;
Intranasal mucosal atomization device: Intranasal atomizer administration of simulated naloxone</description>
          </group>
          <group group_id="O3">
            <title>Intranasal (Spray)</title>
            <description>Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.&#xD;
Nasal spray: Nasal spray administration of simulated naloxone</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Successful Administration of Naloxone</title>
          <description>The time required to successfully administer the simulated naloxone will be reported for each group.</description>
          <units>Seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" lower_limit="50" upper_limit="420"/>
                    <measurement group_id="O2" value="110.3" lower_limit="68.3" upper_limit="288.9"/>
                    <measurement group_id="O3" value="34.3" lower_limit="16.3" upper_limit="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intramuscular Administration</title>
          <description>Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.&#xD;
Syringe and needle: Intramuscular administration of simulated naloxone</description>
        </group>
        <group group_id="E2">
          <title>Intranasal (Atomizer)</title>
          <description>Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.&#xD;
Intranasal mucosal atomization device: Intranasal atomizer administration of simulated naloxone</description>
        </group>
        <group group_id="E3">
          <title>Intranasal (Spray)</title>
          <description>Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.&#xD;
Nasal spray: Nasal spray administration of simulated naloxone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Eggleston</name_or_title>
      <organization>SUNY Upstate Medical University</organization>
      <phone>315-464-8906</phone>
      <email>egglestw@upstate.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

